| abstract |
A composition comprising a compound having the general structure of formula (I): **(See formula)** or a pharmaceutically acceptable salt, solvate, polymorph or tautomer thereof, wherein: -R1 comprises a group with a formula selected from: a) formula (XI): **(See formula)** or b) formula (II): **(See formula)** where: X is SO2 m is an integer independently equal to or greater that 1; - each R2 is independently selected from the group consisting of -OSO3-, -OH, -NH2, -NHSO3-, -NHOCH3 and -OPO3 2-; - each R3 is independently selected from the group consisting of -OSO3-, -OH and -OPO32-; - each R4 is independently selected from the group consisting of -OSO3-, -OH, -OPO32- and -H; - each R5 is independently selected from the group consisting of -CH2OSO3-, -CH2OH, -COO- and -CH2OPO32-; - n is an integer between 3 and 10; for use in treating a lipoprotein metabolism disorder in a subject, wherein said lipoprotein metabolism disorder is selected from the group consisting of diabetes, obesity, metabolic syndrome, xanthoma, hypercholesterolemia, familial hypercholesterolemia, dyslipidemia , hypertriglyceridemia, hyperlipidemia, sitosterolemia, hypertension, angina, acute coronary syndrome, coronary heart disease, atherosclerosis, arteriosclerosis, vascular inflammation and sepsis. |